Cancers (Basel). 2022 Sep 16. pii: 4491. [Epub ahead of print]14(18):
Cheng Chi,
Lisa Harth,
Marina Ramírez Galera,
Marina Passos Torrealba,
Chella Krishna Vadivel,
Carsten Geisler,
Charlotte Menné Bonefeld,
Pia Rude Nielsen,
Michael Bzorek,
Jürgen C Becker,
Lise Mette Rahbek Gjerdrum,
Niels Ødum,
Anders Woetmann.
Cutaneous T cell lymphoma (CTCL) is a group of non-Hodgkin's primary cutaneous T cell lymphomas, with Mycosis Fungoides and Sézary syndrome (SS) being the two most common subtypes. Fatty acid synthase (FASN) is a crucial enzyme that catalyses the biosynthesis of fatty acids, which has been reported to play an oncogenic role in various malignancies but not in CTCL so far. Herein, we show that FASN is highly expressed in CTCL cell lines and in peripheral blood mononuclear cells (PBMCs) from CTCL patients, while it is not in PBMCs from healthy individuals. The inhibition of FASN in CTCL cell lines impairs cell viability, survival, and proliferation, but, interestingly, it also increases FASN expression. However, inhibiting sterol regulatory element binding protein (SREBP), a transcription factor that promotes the expression of FASN, partially reversed the upregulation of FASN induced by FASN inhibitors. Thus, the combination of FASN and SREBP inhibitors enhanced the effects on both CTCL cell lines and PBMCs from SS patients, where a valid inhibition on cell proliferation could be verified. Importantly, compared to non-malignant cells, primary malignant cells are more sensitive to the inhibition of FASN and SREBP, making the combination of FASN and SREBP inhibitors a promising novel therapeutic strategy in CTCL.
Keywords: CTCL; FASN; SREBP; cancer therapy